文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[Cancer incidence and mortality in China, 2022].

作者信息

Zheng R S, Chen R, Han B F, Wang S M, Li L, Sun K X, Zeng H M, Wei W W, He J

机构信息

Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231. doi: 10.3760/cma.j.cn112152-20240119-00035.


DOI:10.3760/cma.j.cn112152-20240119-00035
PMID:38468501
Abstract

The National Central Cancer Registry estimates the number of new cancer cases and deaths in China in 2022, using incidence and mortality data collected by the National Cancer Center. According to the data of 700 cancer registries in 2018 and the data of 106 cancer registries from 2010 to 2018, the age-period-cohort model was used to estimate the incidence rate and mortality rate of all cancers and 23 types of cancer in 2022, stratified by gender and urban and rural areas. We estimated the number of new cancer cases and deaths in China in 2022 based on the estimated rate and population data in 2022. The estimated results showed that in 2022, there were approximately 4 824 700 new cancer cases in China (2 533 900 in males and 2 290 800 in females), with an age-standardized incidence rate of Chinese population (ASIR) of 208.58 per 100 000 (212.67 per 100 000 for males and 208.08 per 100 000 for females). Approximately 2 903 900 new cancer cases occurred in urban areas, with an ASIR of 212.95 per 100 000. It was estimated about 1 920 800 new cancer cases in rural areas, and the ASIR was 199.65 per 100 000. The top five cancers (lung cancer 1 060 600, colorectal cancer 517 100, thyroid cancer 466 100, liver cancer 367 700 and female breast cancer 357 200) accounted for 57.4% of all new cases. The estimated number of deaths from cancer in China in 2022 was 2 574 200 (1 629 300 in males and 944 900 in females), with an age-standardized mortality rate of Chinese population (ASMR) of 97.08 per 100 000 (127.70 per 100 000 in males and 68.67 per 100 000 in females). The number of deaths from cancer in urban and rural areas was about 1 400 600 and 1 173 400, with the ASMR of 92.37 and 103.97 per 100 000 in urban and rural areas, respectively. The top five leading cause of cancers death (lung cancer 733 300, liver cancer 316 500, gastric cancer 260 400, colorectal cancer 240 000 and esophageal cancer 187 500) accounted for 67.5% of all cancer deaths. Lung cancer ranked first in the incidence and mortality in men and women. The incidence rate in urban areas was higher than that in rural areas, while the mortality rate was lower than that in rural areas. The burden of cancer in China is still relatively heavy, with significant differences in cancer patterns in gender, urban-rural, and regional. The burden of cancer presents a coexistence of developed and developing countries, and the situation of cancer prevention and control is still serious in China.

摘要

相似文献

[1]
[Cancer incidence and mortality in China, 2022].

Zhonghua Zhong Liu Za Zhi. 2024-3-23

[2]
[Cancer statistics in China, 2016].

Zhonghua Zhong Liu Za Zhi. 2023-3-23

[3]
[Report of cancer epidemiology in China, 2015].

Zhonghua Zhong Liu Za Zhi. 2019-1-23

[4]
[Report of Cancer Incidence and Mortality in China, 2014].

Zhonghua Zhong Liu Za Zhi. 2018-1-23

[5]
[Analysis of cancer incidence and mortality in elderly population in China, 2013].

Zhonghua Zhong Liu Za Zhi. 2017-1-23

[6]
National cancer incidence and mortality in China, 2012.

Chin J Cancer Res. 2016-2

[7]
Report of incidence and mortality in China cancer registries, 2009.

Chin J Cancer Res. 2013-2

[8]
[Incidence and mortality of female breast cancer in China, 2014].

Zhonghua Zhong Liu Za Zhi. 2018-3-23

[9]
[Incidence and mortality of stomach cancer in China, 2013].

Zhonghua Zhong Liu Za Zhi. 2017-7-23

[10]
[Incidence and mortality of liver cancer in China: an analysis on data from the National Registration System between 2003 and 2007].

Zhonghua Liu Xing Bing Xue Za Zhi. 2012-6

引用本文的文献

[1]
Adaptation and analysis of the psychometric properties of the Chinese version of the MARA questionnaire to assess breast cancer awareness.

Cancer Causes Control. 2025-9-5

[2]
Long-term trends and projections of ovarian cancer burden in China (1990 to 2040): an age-period-cohort analysis based on GBD 2021 data.

Front Oncol. 2025-8-14

[3]
Dosimetric comparison of hybrid IMRT and different arc techniques VMAT after breast-conserving surgery for left-sided breast cancer.

J Appl Clin Med Phys. 2025-9

[4]
A prospective non-randomized interventional study of dynamic changes of L3SMI in patients with gastric cancer undergoing ambulatory chemotherapy with active nutrition combined with exercise.

Front Oncol. 2025-8-13

[5]
VDR Decrease Enhances the Efficacy of 1,25-Dihydroxyvitamin D3 Inhibiting Gefitinib Resistance by Regulating EGFR/FASN Loop in NSCLC Cells.

Pharmaceuticals (Basel). 2025-8-21

[6]
Integrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity.

PLoS Comput Biol. 2025-8-25

[7]
Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.

Discov Oncol. 2025-8-23

[8]
Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.

BMC Cancer. 2025-8-22

[9]
Spermatocytic tumor associated with metastases: report of a rare case and literature review.

Front Pharmacol. 2025-8-4

[10]
A multidimensional comparison of the benefit degrees for patients between ileostomy and colostomy.

Front Med (Lausanne). 2025-8-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索